Leerink Partners maintained a Market Perform rating on CVS Health (NYSE:CVS) shares while increasing the price target from ...

Evercore ISI has updated its outlook on CVS Health (NYSE:CVS) shares, raising the price target from $60.00 to $65.00 while ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

European issuers initially struggled to adapt to the higher cost of funding after a decade of zero to negative interest rates ...

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for ...

Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without ...

Check the time stamp on this data. Updated AI-Generated Signals for Cvs Health Corporation (CVS) available here: CVS. Type a ...

FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.